Key Findings
Evotec has successfully developed a scalable, xeno-free bioprocess platform for the generation of immune-evasive and tumor microenvironment (TME)-resistant iPSC-derived CAR γδ T-cells (CAR iγδ T-cells), specifically designed to target hepatocellular carcinoma (HCC). This platform aims to revolutionize HCC treatment by combining the inherent tissue-homing capabilities and favorable safety profile of γδ T-cells with HCC-specific CAR constructs and strategies for host immune evasion. The ultimate goal is to deliver safe, effective, and cost-efficient ‘off-the-shelf’ CAR T-cell therapies that circumvent the limitations of traditional αβ T-cell-based CAR T approaches, such as the risk of Graft-versus-Host Disease (GvHD) and limited efficacy in solid tumors.
Technical / Clinical Details
The platform developed by Evotec utilizes induced pluripotent stem cells (iPSCs) as the starting material, ensuring an unlimited and reproducible source of CAR γδ T-cells. Unlike conventional αβ T-cells, γδ T-cells recognize tumor cells in an MHC-independent manner, directly targeting stress signals and phosphorylated metabolic intermediates. This unique recognition mechanism allows them to bypass complex antigen presentation pathways and respond to a diverse array of solid tumor antigens. Furthermore, the CAR iγδ T-cells are engineered with specific genetic modifications to evade host immune rejection, facilitating their use as allogeneic (off-the-shelf) products. TME resistance is achieved through engineering strategies that confer resilience against immunosuppressive factors within the TME, such as TGF-β and PD-L1, and enable sustained function under hypoxic and low pH conditions. These combined attributes are expected to unleash potent anti-tumor activity of CAR iγδ T-cells within the challenging HCC microenvironment.
Background & Context
Hepatocellular carcinoma remains a leading cause of cancer-related mortality worldwide, with limited treatment options for advanced-stage disease. While CAR T-cell therapies have demonstrated significant success in hematological malignancies, their efficacy in solid tumors like HCC, characterized by an immunosuppressive TME, has been challenging. This is attributed to poor CAR T-cell infiltration into solid tumors, TME-mediated suppression of cell function, and the risks of GvHD in allogeneic settings. Evotec’s approach represents a pioneering strategy to overcome these hurdles by harnessing the intrinsic biological advantages of γδ T-cells, coupled with scalable iPSC manufacturing and sophisticated immune evasion and TME-resistant engineering.
Strategic Significance & Outlook
This iPSC-derived CAR γδ T-cell manufacturing platform holds immense potential to open new therapeutic avenues for HCC patients. If clinical trials validate its efficacy and safety, it could provide a safe, more effective, and cost-efficient treatment option where current therapies are often inadequate. Beyond HCC, this versatile platform is also applicable to other solid tumor indications, positioning it as a foundational technology for future immune cell therapy development. This advancement is expected to accelerate the commercialization of allogeneic CAR T-cell therapies and significantly broaden patient access to these life-saving treatments globally, marking a pivotal step in the fight against solid cancers.
Source: https://www.news-medical.net/whitepaper/20260918/iPSC-derived-CAR-T-cells-for-liver-cancer.aspx
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments